This implies that DPP4is, characterized by their small molecular size (below 500 Da), can effectively hinder the enzyme's catalytic site, inhibiting its function, while preserving the molecule's capacity to act as a costimulatory factor without disruption
Studies show that weight regain is common within 12 months of discontinuing GLP-1 therapy, with many individuals regaining two-thirds of what they lost (PubMed)
Survodutide (BI 456906) is a GLP-1R/GCGR dual agonist developed by Boehringer Ingelheim, with outcomes of a phase 2 trial in MASLD and a phase 1 trial in cirrhosis published almost simultaneously with tirzepatide
There's no definitive evidence that Melanotan II causes cancer
Reviews and experimental reports of nanoparticle-in-gel and other loco-regional radiosensitizer strategies provide mechanistic evidence that sustained local retention increases tumor uptake and dose enhancement while reducing systemic toxicity, a pattern replicated across several tumor models [72, 181, 182]
This absence of datarather than evidence of harmis why healthcare providers typically advise caution
